Table of Contents Table of Contents
Previous Page  69 / 1851 Next Page
Information
Show Menu
Previous Page 69 / 1851 Next Page
Page Background

I-SPY 2 TRIAL

HER2 (HSP90, HER2, HER3)

IGFR

PI3K

Macrophage

AKT

AKT + MAPK, ERBB2, or PI3K+MEK inhibitors

Death Receptor

c-MET

mTOR + X

Angiogenesis + X